The Journal of Bone and Joint Surgery (American). 2007;89:102-113.
doi:10.2106/JBJS.F.00198
© 2007 The Journal of Bone and Joint Surgery, Inc.
Epiphysiodesis with Infusion of Stromal Cell-Derived Factor-1 in Rabbit Growth Plates
Mark C. Lee, MD1,
Adam D. Bier, MD1,
Florian Nickisch, MD2,
Craig P. Eberson, MD1,
Michael G. Ehrlich, MD1 and
Qian Chen, PhD3
1 Department of Orthopaedics, Rhode Island Hospital and Brown University School
of Medicine, 593 Eddy Street, Providence, RI 02908
2 Division of Orthopaedic Surgery, Duke University Medical Center, Box 3093,
Durham, NC 27705
3 Department of Orthopaedics, Rhode Island Hospital and Brown University School
of Medicine, CORO West, 1 Hoppin Street, 402A, Providence, RI 02903. E-mail
address:
Qian_Chen{at}brown.edu
Investigation performed at the Department of Orthopaedics, Rhode Island
Hospital and Brown University School of Medicine, Providence, Rhode
Island
Disclosure: The authors did not receive grants or outside funding in
support of their research for or preparation of this manuscript. They did not
receive payments or other benefits or a commitment or agreement to provide
such benefits from a commercial entity. No commercial entity paid or directed,
or agreed to pay or direct, any benefits to any research fund, foundation,
educational institution, or other charitable or nonprofit organization with
which the authors are affiliated or associated.
Background: The mechanism of physeal closure is poorly understood,
although both mechanical and biological factors may play a role in the
process. In this study, we evaluated the effect of the application of a
chemokine stromal cell-derived factor-1 (SDF-1) to rabbit physes in vivo with
regard to growth inhibition.
Methods: A continuous infusion system consisting of a fenestrated
catheter and an osmotic pump were implanted into the right proximal tibial
physis of twenty six-week-old New Zealand White rabbits. Ten of the pumps were
loaded with human recombinant SDF-1 , and ten were loaded with
phosphate-buffered saline solution (sham treatment). The left leg was used as
the uninvolved control. The growth of the tibiae was followed radiographically
for eight weeks, and histologic analysis was performed for both the
SDF-1-treated rabbits and the sham-treated rabbits at two, four, and
eight-week time-points.
Results: Radiographic evaluation showed a significant growth
inhibition in the SDF-1 -treated physes (4.5 ± 3.0 mm; p = 0.007)
compared with the sham-treated physes after eight weeks. No difference was
noted when the sham-treated leg was compared with the contralateral, control
leg (0.2 ± 2.9 mm; p = 0.465). Histologic evaluation showed marked
physeal disorganization, narrowing, and proteoglycan loss and a significant
decrease in physeal height (p < 0.0001) for the SDF-1-treated group.
Reversible growth slowing was noted in the uninvolved, control leg of the
SDF-1-treated group at six weeks, with resolution of the difference by eight
weeks.
Conclusions: SDF-1 may be used to induce physeal closure through a
targeted infusion system. However, transient systemic effects of SDF-1 may
exist and must be evaluated further prior to its clinical use for
epiphysiodesis.
Clinical Relevance: The use of biologic agents to effect physeal
closure could offer a biological therapeutic alternative to mechanical
ablation of the physis for the treatment of limb-length inequality in
children.

CiteULike Connotea Del.icio.us Technorati What's this?
|